Books/Book Chapters/Edited Books
Permanent URI for this collectionhttp://192.168.24.11:4000/handle/123456789/237
Browse
66 results
Search Results
Item Curcumin as Neuroprotective Agent(CRC Press/Taylor & Francis, 2026) Naureen Rizvi, Mohd Muazzam Khan, Usama AhmadThe occurrence of specific pathological abnormalities in the brain, such as cellular inclusions, protein deposits outside cells, and changes in cell shape, is a defining characteristic of neurodegeneration. Besides acute neurodegenerative conditions like ischemic stroke and hemorrhagic stroke, OS might play a causal part in the development of progressive neurodegenerative disorders like PD and AD. Antioxidants that protect neurons are thought to be a promising strategy for reducing extent and speed of death of neurons in certain illnesses. Curcumin, polyphenolic substance discovered in the tuber of turmeric which is also called Curcuma longa, has been identified as an active agent when treating a variety of central nervous system diseases, exhibits multiple pharmacological impacts, making it a versatile component. It is well known for its potent antioxidant, and that is well documented to possess multifunctional therapeutic benefits for various chronic conditions. In ailments like AD, major depressive disorder, tardive dyskinesia, epilepsy, and other related neurodegenerative and neuropsychiatric conditions, curcumin exhibits neuroprotective qualities. It effectively suppresses the expression of reactive astrocytes, preventing cell death, and also regulates several neurotransmitter levels in the brain. In this review, we will focus on the current state of the art of curcumin as a potential remedy for various neurological conditions.Item Herbal Formulation Development(Book Rivers, 2026) Irfan AzizItem Basics of Drug Design(Book Rivers, 2026) Irfan AzizItem Novel Drug Delivery Systems(Book Rivers, 2026) Widhilika SinghItem Nanotechnology in Drug Delivery(Book Rivers, 2026) Widhilika SinghItem Future Trends in Pharmaceutical Sciences(Book Rivers, 2026) Nazish NaseemItem Regulatory Aspects of Herbal and Synthetic Drugs(Book Rivers, 2026) Nazish NaseemItem Foundations and Advances in Pharmaceutical Sciences(Book Rivers, 2026) Anas IslamItem Patent Strategies and Intellectual Property Management in Nanotechnology Based Drug Delivery(IJPHI Global Publisher Pvt. Ltd., 2026) Himanshu Singh, Abdul Baseer Khan, Harshit Verma, Vandana Tiwari, Sushma CahudharyThe development of nanotechnology-based drug delivery systems has revolutionized modern drug research by providing targeted drug delivery, improving drug efficacy, controlling drug release, and minimizing systemic drug toxicity effects. A wide range of nanocarriers, such as liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, nanocrystals, and lipid-based nanocarriers, have been developed in recent years owing to the rapid progress in nanomedicine. The protection of intellectual property (IP) has become an integral component in the protection of innovation, attracting investment, and successful commercialization of these technologies as they move from the laboratory to commercial products. Strategies to protect new formulations, manufacturing processes, surface modifications, and therapeutic uses are key factors in successful patent protection in the face of changing regulatory and legal conditions. This chapter provides a detailed account of IP management and patent strategies in nanotechnology-based drug delivery. It provides an overview of the basics of IP rights, such as patents, copyrights, trademarks, and trade secrets, with a focus on the application of patent protection to innovations in nano pharmaceuticals. The chapter discusses the conditions for patentability, the analysis of prior art, drafting patents, patent filing process, and international patent protection mechanisms. It also explores issues of patenting nanomedicines, including overlapping technologies, regulation, freedom to operate, and issues of lifecycle management. Recent case studies and new trends in AI-driven patent analytics. global patent landscapes, and commercialization strategies are also emphasized. This chapter is designed to offer practical insights to researchers, academics, industry professionals, and policymakers in the field of protecting and commercializing nanotechnology-based drug delivery systems into viable pharmaceutical products by combining scientific innovation with IP management.Item Recent progress in CAR-T cell therapy for B-cell cancers with resistant tissues(Academic Press, 2026) Rajesh Kumar , Seetha Harilal , Mohd Aftab Siddiqui , Mohhammad Ramzan , Sumel AshiqueThe therapy of B-cell cancers, particularly lymphomas, has undergone a tremendous change with the approval of chimeric antigen receptor (CAR)-T cell therapy, and is currently widely available, which can be considered as a standard therapeutic option, in the case of patients having aggressive lymphomas, even though being utilized after multiple lines of treatment. The current CAR-T cell therapies, which are approved by the FDA works by targeting the antigens such as CD19 or BCMA present in the B cells. The CAR-T cell therapies are rapidly advancing with new findings to address the current limitations, including toxicities, and resistance; such as targeting multiple antigens, the source and the delivery of genetic material into the T cells, utilization of nanotechnology, as well as mRNA-based strategies, utilization of another type of immune cells such as the natural killer cells, as well as incorporating gene editing strategies. A large number of studies, including preclinical and clinical trials, are conducted to translate the findings from the bench to the bedside. The chapter discusses the CAR-T cell therapy, the mechanism, approved therapies, limitations, including toxicities, and resistance, and recent advancements in research, particularly in the therapy of B-cell cancers.